BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 34631713)

  • 1. Characterization of Molecular Heterogeneity Associated With Tumor Microenvironment in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy.
    Zhong W; Li Y; Yuan Y; Zhong H; Huang C; Huang J; Lin Y; Huang J
    Front Cell Dev Biol; 2021; 9():736540. PubMed ID: 34631713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 4. Neutrophil extracellular traps-associated modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of clear cell renal cell carcinoma.
    Teng ZH; Li WC; Li ZC; Wang YX; Han ZW; Zhang YP
    Front Oncol; 2022; 12():1094248. PubMed ID: 36620592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Hypoxia-Related Molecular Subtypes in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy and Targeted Therapy
    Zhong W; Zhong H; Zhang F; Huang C; Lin Y; Huang J
    Front Mol Biosci; 2021; 8():684050. PubMed ID: 34250018
    [No Abstract]   [Full Text] [Related]  

  • 6. Construction of an interferon regulatory factors-related risk model for predicting prognosis, immune microenvironment and immunotherapy in clear cell renal cell carcinoma.
    Pan H; Lu W; Zhang M; Liu C
    Front Oncol; 2023; 13():1131191. PubMed ID: 37182129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients.
    Yao J; Liang Z; Duan L; G Y; Liu J; An G
    Heliyon; 2023 Jun; 9(6):e15925. PubMed ID: 37484396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of Clear Cell Renal Cell Carcinoma based on Tumor Suppressor Genomic Profiling.
    Zhong W; Zhang F; Huang C; Lin Y; Huang J
    J Cancer; 2021; 12(8):2359-2370. PubMed ID: 33758612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
    Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
    Front Immunol; 2022; 13():861328. PubMed ID: 35479084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of molecular subtypes and diagnostic model in clear cell renal cell carcinoma based on collagen-related genes may predict the response of immunotherapy.
    Hong Y; Lv Z; Xing Z; Xu H; Chand H; Wang J; Li Y
    Front Pharmacol; 2024; 15():1325447. PubMed ID: 38375034
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of Epithelial-Mesenchymal Transition-Related lncRNA With Prognosis and Molecular Subtypes in Clear Cell Renal Cell Carcinoma.
    Zhong W; Zhang F; Huang C; Lin Y; Huang J
    Front Oncol; 2020; 10():591254. PubMed ID: 33324563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A signature based on m6A pattern and tumor microenvironment infiltration in clear cell renal cell carcinoma.
    Yang C; Yu T; Li Q; Xie F; Lin Q
    Am J Transl Res; 2022; 14(7):4931-4947. PubMed ID: 35958449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
    Chen Y; He J; Jin T; Zhang Y; Ou Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis, Immune Microenvironment Infiltration and Immunotherapy Response in Clear Cell Renal Cell Carcinoma Based on Cuproptosis-related Immune Checkpoint Gene Signature.
    Liu G; Li F; Ge Y; Shi Y; Ren F; Zhu L
    J Cancer; 2023; 14(17):3335-3350. PubMed ID: 37928426
    [No Abstract]   [Full Text] [Related]  

  • 17. Establishment of a prognosis Prediction Model Based on Pyroptosis-Related Signatures Associated With the Immune Microenvironment and Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma.
    Jiang A; Meng J; Bao Y; Wang A; Gong W; Gan X; Wang J; Bao Y; Wu Z; Lu J; Liu B; Wang L
    Front Oncol; 2021; 11():755212. PubMed ID: 34804944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
    Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
    Front Immunol; 2022; 13():890150. PubMed ID: 35686121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
    Tai R; Leng J; Li W; Wu Y; Yang J
    BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
    Gao J; Ye F; Han F; Jiang H; Zhang J
    Front Immunol; 2022; 13():956679. PubMed ID: 36177018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.